Literature DB >> 14692021

Uncertain benefit from surgery in patients with lung metastases from breast carcinoma.

David Planchard1, Jean-Charles Soria, Stefan Michiels, Dominique Grunenwald, Pierre Validire, Raffaele Caliandro, Philippe Girard, Thierry Le Chevalier.   

Abstract

BACKGROUND: Isolated lung metastases have been reported to occur in 10-20% of all women with breast carcinoma. The authors described a series of patients who underwent surgery for lung metastases from breast carcinoma.
METHODS: They reviewed the files of 125 consecutive patients who underwent surgery with a curative intent for lung metastases from breast carcinoma between 1972 an 1998 at a single institution. Survival curves were plotted by the Kaplan-Meier method. Prognostic factors were identified using the log-rank test and a Cox proportional hazards model for univariate and multivariate analyses, respectively.
RESULTS: The median age at surgery was 53 years. There was a median of 1 resected metastasis (range, 1-16 resected metastases). The median size of the largest metastasis was 19 mm (range, 5-70 mm). The median disease-free interval (DFI) was 3 years. The median follow-up time after surgery was 8.5 years (range, 25 days to 22 years). The 3-year, 5-year, and 10-year probabilities of survival were 58% (95% confidence interval [95% CI], 49-67%), 45% (95% CI, 36-55%), and 30% (95% CI, 21-41%), respectively. The median survival time after surgery was 4.2 years. Complete resection was achieved in 96 patients. The quality of the resection (complete vs. incomplete) was not a statistically significant prognostic factor by univariate analysis and there was no significant difference between these two groups in terms of adjuvant postoperative therapy. The characteristics of the primary tumor and the number of metastases (one vs. two or more) had no detectable influence on survival. The size of the largest metastasis (> 20 mm or < or = 20 mm) and the DFI (< or = 3 years vs. > 3 years) were highly significant prognostic factors (P = 0.006 and P = 0.003, respectively). This was confirmed by multivariate analysis. Patients with a DFI < or = 3 years and/or the largest metastasis > 20 mm reportedly had a poor outcome (median survival, 2.6 years vs. 8.5 years for patients with none of these poor prognostic factors).
CONCLUSIONS: Resection of lung metastases from breast carcinoma was associated with a significant 5-year survival rate of 45%. Whether these encouraging findings resulted from the surgical procedure itself or the preoperative selection of patients remained uncertain. When surgery is considered in this setting, the size of the largest metastasis and the DFI should be taken into account.

Entities:  

Mesh:

Year:  2004        PMID: 14692021     DOI: 10.1002/cncr.11881

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

Review 1.  Improvement of survival and prospect of cure in patients with metastatic breast cancer.

Authors:  Yee Chung Cheng; Naoto T Ueno
Journal:  Breast Cancer       Date:  2011-05-13       Impact factor: 4.239

2.  Radio-photothermal therapy mediated by a single compartment nanoplatform depletes tumor initiating cells and reduces lung metastasis in the orthotopic 4T1 breast tumor model.

Authors:  Min Zhou; Jun Zhao; Mei Tian; Shaoli Song; Rui Zhang; Sanjay Gupta; Dongfeng Tan; Haifa Shen; Mauro Ferrari; Chun Li
Journal:  Nanoscale       Date:  2015-12-14       Impact factor: 7.790

Review 3.  Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look?

Authors:  Barbara A Pockaj; Nabil Wasif; Amylou C Dueck; Dennis A Wigle; Judy C Boughey; Amy C Degnim; Richard J Gray; Sarah A McLaughlin; Donald W Northfelt; Robert P Sticca; James W Jakub; Edith A Perez
Journal:  Ann Surg Oncol       Date:  2010-03-16       Impact factor: 5.344

Review 4.  Current controversies in the management of breast cancer.

Authors:  I Tusquets; L García-Estévez; E Adrover; L Calvo; I Alvarez; J García Mata; Y Fernández; M Margueli; M A Seguí; M Muñoz; C Rodríguez; A Rodríguez Lescure; R Colomer; P Gascón; M Martín; E Alba; A Barnadas; A Llombart; J Albanell; A Lluch
Journal:  Clin Transl Oncol       Date:  2010-04       Impact factor: 3.405

5.  Prognostic factors for resection of isolated pulmonary metastases in breast cancer patients: a systematic review and meta-analysis.

Authors:  Jun Fan; Dali Chen; Heng Du; Cheng Shen; Guowei Che
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

Review 6.  Surgical intervention for pulmonary metastases.

Authors:  Joachim Pfannschmidt; Gerlinde Egerer; Marc Bischof; Michael Thomas; Hendrik Dienemann
Journal:  Dtsch Arztebl Int       Date:  2012-10-05       Impact factor: 5.594

Review 7.  Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression.

Authors:  Fausto Petrelli; Sandro Barni
Journal:  Med Oncol       Date:  2012-07-28       Impact factor: 3.064

8.  Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models.

Authors:  Abhik Bandyopadhyay; Long Wang; Joseph Agyin; Yuping Tang; Shu Lin; I-Tien Yeh; Keya De; Lu-Zhe Sun
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

Review 9.  Pulmonary metastasectomy: an overview.

Authors:  Francesco Petrella; Cristina Diotti; Arianna Rimessi; Lorenzo Spaggiari
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

10.  Lung Metastasectomy for Pulmonary Metastatic Breast Carcinoma.

Authors:  Sascha Macherey; Peter Mallmann; Wolfram Malter; Fabian Doerr; Matthias Heldwein; Thorsten Wahlers; Khosro Hekmat
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-06-28       Impact factor: 2.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.